NSE: EMCURE · 9 November 2026
- Emcure Pharmaceuticals has risen 17.60% over 5 trading sessions; today's move is -2.80%.
- Emcure Pharmaceuticals submitted its financial results for the quarter ended September 30, 2026, reporting operating revenue of ₹28,205 million and a net profit of ₹3,251 million. Operating revenue grew by 24.3% year-on-year, while profit after tax expanded by 29.3% compared to the same period last year. The results reflect sustained performance across both domestic branded generics and international markets including Europe, Canada, and the Rest of World.
- Trading volume was 1.18 times the 20-day average daily volume.
Emcure Pharmaceuticals share price: 17.60% rise over 5 trading sessions
Emcure Pharmaceuticals Ltd. (EMCURE) declined 2.80% today, closing at ₹2,216.20 after touching an intraday high of ₹2,280.00 and a low of ₹2,196.60.
While the broader market benchmark Nifty edged up by 0.06%, the sector benchmark Nifty Pharma recorded a strong gain of 3.42%. Emcure's downward movement ran counter to the positive momentum seen across the broader pharmaceutical sector, reflecting localized selling pressure or profit-taking following its recent 5-day return of 17.60% and 20-day return of 20.81%.
In recent fundamental updates, the company reported its financial results for the quarter ended September 30, 2026, highlighting a 24.3% YoY increase in operating revenue to ₹28,205 million and a 29.3% YoY rise in profit after tax to ₹3,251 million. Additionally, the company received Income-tax Department penalty orders totaling ₹57.73 crore for assessment years spanning 2015-16 to 2021-22, which the management is currently evaluating for appropriate legal remedies.
2.60 lakh shares traded by 9 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 2.21 lakh shares (1.18 times). The five-day average daily volume was 6.10 lakh shares. Separately, the NSE report for 9 November 2026 showed 1.35 lakh shares delivered, representing 51.98% of that day’s traded volume. The same report recorded 40,877 trades.
The stock retreated 2.80% despite a positive sector backdrop, indicating near-term profit-taking after strong multi-day gains (17.60% over 5 days). Volume remained moderately active at 1.18 times its 20-day average, with no specific single catalyst directly driving the day's pullback.
Latest Company Developments
Emcure Pharmaceuticals submitted its financial results for the quarter ended September 30, 2026, reporting operating revenue of ₹28,205 million and a net profit of ₹3,251 million. Operating revenue grew by 24.3% year-on-year, while profit after tax expanded by 29.3% compared to the same period last year. The results reflect sustained performance across both domestic branded generics and international markets including Europe, Canada, and the Rest of World.
Quarterly earnings figures directly dictate fundamental valuation, revenue growth trajectories, and operational leverage for the company.
The company disclosed the receipt of various orders from the Income-tax Department, Pune, imposing an aggregate penalty of ₹57,73,96,732 for financial years ranging from 2014-15 to 2020-21. Emcure stated that it is actively evaluating appropriate legal remedies, including filing appeals before the relevant Appellate Authority. These tax demands pertain to ongoing legacy disputes disclosed previously in governance filings.
Tax liabilities and regulatory penalties represent potential cash outflows that require ongoing legal management and contingent risk assessment.
The Board of Directors approved a proposed Scheme of Amalgamation involving wholly owned subsidiaries Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited with the holding company, Emcure Pharmaceuticals Limited. The restructuring is subject to requisite statutory and regulatory approvals. It forms part of the 'One Emcure' vision to simplify the group holding structure and achieve operational synergies.
Corporate restructurings can streamline backend operations and corporate functions, supporting long-term structural efficiency.
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Emcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries with Emcure Pharmaceuticals Limited – Holding Company, subject to requisite statutory and regulatory approvals.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 7.05% on 30 September 2026. This compares with 6.87% on 30 June 2026, a change of +0.18 percentage points.
The filing reported 23 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Progress on the proposed amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals with the holding company
- Developments regarding the income-tax penalty appeals and legal evaluations
- Sustained delivery volumes relative to the 20-day average volume of 1.18x
- Performance execution in key domestic therapy segments including women's health and cardio-metabolics
Other Dated Coverage
- Emcure Pharmaceuticals Share Price Today: Rises 11.95% in 3 Trading Sessions | 6 November 2026 — 6 November 2026
- Emcure Pharmaceuticals Share Price Today: Rises 15.43% in 2 Trading Sessions | 4 November 2026 — 4 November 2026
- Emcure Pharmaceuticals Share Price Jumps 10.00% Intraday, Closes 4.94% Higher | 3 November 2026 — 3 November 2026
More Emcure Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Emcure Pharmaceuticals company news?
Emcure Pharmaceuticals submitted its financial results for the quarter ended September 30, 2026, reporting operating revenue of ₹28,205 million and a net profit of ₹3,251 million. Operating revenue grew by 24.3% year-on-year, while profit after tax expanded by 29.3% compared to the same period last year. The results reflect sustained performance across both domestic branded generics and international markets including Europe, Canada, and the Rest of World.
How strong was Emcure Pharmaceuticals’s trading volume?
2.60 lakh shares traded, 1.18 times the 20-day average daily volume. The price and volume data are dated 9 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.